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BACKGROUND
Selinexor, a selective inhibitor of nuclear export compound that blocks exportin 1 
(XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins, 
inhibits nuclear factor κB, and reduces oncoprotein messenger RNA translation, is a 
potential novel treatment for myeloma that is refractory to current therapeutic options.
METHODS
We administered oral selinexor (80 mg) plus dexamethasone (20 mg) twice weekly to 
patients with myeloma who had previous exposure to bortezomib, carfilzomib, lena­
lidomide, pomalidomide, daratumumab, and an alkylating agent and had disease 
refractory to at least one proteasome inhibitor, one immunomodulatory agent, and 
daratumumab (triple­class refractory). The primary end point was overall response, 
defined as a partial response or better, with response assessed by an independent 
review committee. Clinical benefit, defined as a minimal response or better, was a 
secondary end point.
RESULTS
A total of 122 patients in the United States and Europe were included in the modified 
intention­to­treat population (primary analysis), and 123 were included in the safety 
population. The median age was 65 years, and the median number of previous regi­
mens was 7; a total of 53% of the patients had high­risk cytogenetic abnormalities. A 
partial response or better was observed in 26% of patients (95% confidence interval, 
19 to 35), including two stringent complete responses; 39% of patients had a minimal 
response or better. The median duration of response was 4.4 months, median progres­
sion­free survival was 3.7 months, and median overall survival was 8.6 months. Fa­
tigue, nausea, and decreased appetite were common and were typically grade 1 or 2 
(grade 3 events were noted in up to 25% of patients, and no grade 4 events were re­
ported). Thrombocytopenia occurred in 73% of the patients (grade 3 in 25% and grade 
4 in 33%). Thrombocytopenia led to bleeding events of grade 3 or higher in 6 patients.
CONCLUSIONS
Selinexor–dexamethasone resulted in objective treatment responses in patients with 
myeloma refractory to currently available therapies. (Funded by Karyopharm Thera­
peutics; STORM ClinicalTrials.gov number, NCT02336815.)
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Despite the availability of protea-some inhibitors, immunomodulatory agents, and monoclonal antibodies for 
multiple myeloma, most patients will have a 
relapse and refractory disease will develop. An 
increasing number of patients have triple­class 
refractory myeloma, defined as disease refrac­
tory to proteasome inhibitors, immunomodula­
tory agents, and monoclonal antibodies, with 
most patients being treated with all five agents 
currently in use (carfilzomib, bortezomib, lena­
lidomide, pomalidomide, and daratumumab; i.e., 
penta­exposed). Overall survival in patients with 
myeloma refractory to these classes is short; 
patients with daratumumab­refractory myelo­
ma have a median overall survival of 1.7 to 3.0 
months.1­4 Currently, these patients have no 
treatment options with proven clinical benefit.4,5
Exportin 1 (XPO1) — the sole known nuclear 
exporter of tumor suppressor proteins, the gluco­
corticoid receptor, and oncoprotein messenger 
RNAs (mRNAs) — is overexpressed in myeloma 
and correlates with increased bone disease and 
shorter survival.6­11 Selinexor, which was recently 
approved by the Food and Drug Administration, 
is a potent, oral, selective inhibitor of nuclear 
export that binds to Cys528 in the cargo­binding 
pocket of XPO1,12­14 forcing the nuclear localiza­
tion and functional activation of tumor­suppres­
sor proteins, trapping IκBα in the nucleus to 
suppress nuclear factor κB activity, and prevent­
ing oncoprotein mRNA translation.9,10,15 Selective 
induction of apoptosis in malignant hemato­
logic and solid tumor cells is a result.9 Preclini­
cal studies have shown that selinexor with or 
without dexamethasone induces apoptosis in a 
number of myeloma cell lines and has antitumor 
activity in animal models.3,8,9,16,17
Administration of selinexor (80 mg) with 
dexamethasone (20 mg) according to two dosing 
schedules had been evaluated among patients 
with myeloma refractory to either four or five 
drugs in Part 1 of the phase 2 STORM (Selinex­
or Treatment of Refractory Myeloma) study.18 In 
that heterogeneous population, 21% of patients 
had a partial response or better. On the basis of 
those findings, the activity of selinexor at a dose 
of 80 mg twice weekly was examined in a more 
uniform population in the pivotal STORM Part 2 
study.
Me thods
Trial Design and Oversight
The STORM study was a phase 2b, multicenter, 
open­label study involving patients enrolled 
from May 2015 through March 2018 at 60 sites 
in the United States and Europe. The institu­
tional review board or independent ethics com­
mittee at each study center approved the proto­
col (available with the full text of this article at 
NEJM.org), and the study was performed in ac­
cordance with the International Conference on 
Harmonisation Good Clinical Practice guidelines 
and the principles of the Declaration of Helsinki. 
The study was designed by the sponsor (Karyo­
pharm Therapeutics). Disease response was ad­
judicated by an independent review committee 
of four physicians. The sponsor collected the 
data and analyzed them in conjunction with the 
authors. A professional medical writer, funded 
by the sponsor, wrote the first draft of the 
manuscript under close direction of the authors. 
The authors reviewed and revised the manu­
script, had access to all data, and vouch for the 
completeness and accuracy of the data and for 
the adherence of the study to the protocol.
Patients
Eligible patients had measurable myeloma accord­
ing to International Myeloma Working Group 
(IMWG) criteria19,20 (see the Supplementary Ap­
pendix, available at NEJM.org); had previously 
received treatment with bortezomib, carfilzomib, 
lenalidomide, pomalidomide, daratumumab, glu­
cocorticoids, and an alkylating agent; and had 
disease refractory to at least one immunomodu­
latory drug, one proteasome inhibitor, daratumu­
mab, glucocorticoids, and their most recent 
regimen. Refractory disease was defined as 
progression during treatment or within 60 days 
after completion of therapy, or less than 25% 
response to therapy.19,20 An Eastern Cooperative 
Oncology Group performance­status score of 
0 to 2 (scores range from 0 to 5, with higher 
scores reflecting greater disability) and adequate 
hepatic function, renal function, and hemato­
poietic function were required. Systemic light­
chain amyloidosis, active central nervous system 
involvement, peripheral neuropathy of grade 3 
or higher, or painful neuropathy of grade 2 or 
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higher were exclusion criteria. A full list of inclu­
sion and exclusion criteria is provided in Table S1 
in the Supplementary Appendix. Written informed 
consent was obtained from all patients before 
enrollment.
Treatment
Oral selinexor (80 mg) in combination with 
dexamethasone (20 mg) was administered on 
days 1 and 3, weekly, in 4­week cycles until dis­
ease progression, death, or discontinuation. A 
dose­modification protocol was used for the 
management of adverse events (Tables S2 and S3 
in the Supplementary Appendix). All patients 
were required to receive 8 mg of ondansetron (or 
equivalent) before the first dose of study drug 
and two or three times daily as needed. Other 
antiemetics (olanzapine and neurokinin­1 recep­
tor antagonists) were permitted for patients with 
unacceptable side effects to ondansetron (or its 
equivalent) or with persistent nausea. Supportive 
measures were provided at the discretion of the 
investigator and may have included intravenous 
f luids, hematopoietic growth factors, transfu­
sions, appetite stimulants (olanzapine and meges­
trol acetate), or a combination of these.
End Points and Assessments
The primary end point was overall response, 
defined as a confirmed partial response (≥50% 
reduction in the serum level of myeloma protein) 
or better, with response adjudicated by the inde­
pendent review committee.21 Secondary end points 
included response duration; clinical benefit, de­
fined as a confirmed minimal response (≥25 to 
<50% reduction in the serum level of myeloma 
protein) or better; progression­free survival; and 
overall survival. (Definitions of end points are 
provided in the Supplementary Appendix.) Disease­
specific assessments were conducted at baseline, 
day 1 of each treatment cycle, and at the time of 
disease progression or suspected response. High­
risk cytogenetic abnormalities included del(17p), 
t(4;14), t(14;16), and gain(1q) chromosomal abnor­
malities on fluorescence in situ hybridization.22 
Quality of life was assessed with the Functional 
Assessment of Cancer Therapy–Multiple Myeloma 
questionnaire (see the protocol). Safety and side­
effect profile were assessed through history tak­
ing, physical examination, laboratory assessments, 
and 12­lead electrocardiography. Adverse events 
were graded according to the National Cancer 
Institute Common Terminology Criteria for Ad­
verse Events, version 4.03.23
Pharmacodynamics and Response Predictor
Methods regarding measurement of XPO1 mRNA 
induction and immunohistochemical analysis of 
glucocorticoid receptor induction are included in 
the Supplementary Appendix. A predictive bio­
marker of response to selinexor was sought in 
patients with myeloma with the use of the VIPER 
(Virtual Inference of Protein­activity by Enriched 
Regulon analysis) algorithm, which can trans­
form gene­expression profiles from tumor sam­
ples into accurate predictions of protein activ­
ity for approximately 6000 regulatory proteins 
(DarwinHealth) (see the Supplementary Appen­
dix).24 RNA levels in CD138+ cells that were 
isolated from the pretreatment bone marrow 
aspirate of patients enrolled in the STORM Part 2 
study were used for this analysis.
Statistical Analysis
The sample size was based on assumptions for 
penta­exposed, triple­class refractory myeloma 
with a minimal threshold of 10% of patients 
with a partial response or better.19 For the pri­
mary efficacy analysis, a sample of 122 patients 
allowed for a one­sided test at an alpha level of 
0.025 to detect a minimum of 20% of patients 
with a partial response or better against a value 
of 10% under the null hypothesis with 90% 
power. The modified intention­to­treat popula­
tion was used for the primary efficacy analysis; 
this population comprised all enrolled patients 
who met all eligibility criteria or received a 
waiver to enroll from the sponsor (12 patients; 
waivers were granted only in situations in which 
patient safety was not compromised and the 
scientific integrity of the study was not affected) 
and who received at least one dose of selinexor 
plus dexamethasone. The safety population in­
cluded all patients who received at least one dose 
of study drug. The primary analysis used a two­
sided, exact 95% confidence interval, calculated 
for the percentage of patients with a partial 
response or better in the modified intention­to­
treat population, with statistical significance 
declared if the lower boundary of this interval 
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was more than 10%. Summary statistics were 
computed and displayed for each of the defined 
analysis populations and according to each as­
sessment time point. Summary statistics for con­
tinuous variables minimally included number, 
mean, standard deviation, minimum, median, 
and maximum. For categorical variables, frequen­
cies and percentages are presented. For time­to­
event variables, the Kaplan–Meier method was 
used for descriptive summaries.
R esult s
Patients
A total of 123 patients were enrolled, all of 
whom were included in the safety population 
(Fig. S1 in the Supplementary Appendix). One 
patient did not meet full eligibility criteria (no 
previous carfilzomib); therefore, 122 patients 
were included in the modified intention­to­treat 
population. The median age was 65.2 years, and 
the median duration of myeloma was 6.6 years; 
53% of the patients had high­risk cytogenetic 
abnormalities (Table 1, and Table S4 in the 
Supplementary Appendix). All patients had pro­
gressive myeloma at the time of enrollment, and 
the disease was typically rapidly progressive: 107 
patients (88%) with available data on myeloma 
protein levels at both screening and the first day 
of therapy (median, 12 days) had a median in­
crease in disease burden of 22%. Creatinine 
clearance was less than 60 ml per minute in 39 
patients (32%) and less than 40 ml per minute 
in 14 patients (11%). The median number of 
previous therapies was 7 (range, 3 to 18); 86 
patients (70%) had previously received daratumu­
mab in combination with other agents, 102 (84%) 
had previously undergone stem­cell transplanta­
tion, and 2 (2%) had previously received chime­
ric antigen receptor T­cell (CAR­T) therapy. In the 
modified intention­to­treat population, all pa­
tients had penta­exposed myeloma that was re­
fractory to at least one proteasome inhibitor, one 
immunomodulatory drug, and daratumumab, as 
required by the protocol. A total of 83 patients 
(68%) were documented to have penta­refractory 
myeloma. It is notable that 96% of the patients 
had myeloma that was refractory to the most 
potent agent of each class: carfilzomib, pomalid­
omide, and daratumumab (Table 1).
Treatment Duration and Doses
Of the 123 patients enrolled, 118 (96%) discon­
tinued treatment, with disease progression and 
adverse events the most common reasons (Table 
S1 in the Supplementary Appendix). At the last 
date of follow­up (August 17, 2018), 5 patients 
(4%) continued to receive treatment; 34 (28%) 
had discontinued treatment and remained in 
follow­up for long­term survival. The median 
duration of treatment with selinexor plus dexa­
methasone was 9.0 weeks (range, 1 to 60).
Efficacy
A partial response or better was observed in 26% 
of patients (95% confidence interval [CI], 19 to 35), 
including 2 stringent complete responses (in 2% 
of the patients), 6 very good partial responses (in 
5%), and 24 partial responses (in 20%) (Table 2); 
because the lower boundary of the confidence 
interval was more than 10%, the trial met its 
primary end point. Both patients with relapse 
after CAR­T therapy had a partial response. 
Minimal response according to IMWG criteria 
was observed in 16 patients (13%), and 48 pa­
tients (39%) had stable disease, whereas 26 (21%) 
had progressive disease or disease that could not 
be evaluated for response. The median time to a 
partial response or better was 4.1 weeks (range, 
1 to 14). A minimal response or better was 
observed in 39% of patients (95% CI, 31 to 49). 
Additional response analyses are shown in Ta­
ble 2. The median duration of response was 
4.4 months (95% CI, 3.7 to 10.8) (Fig. 1). The 
median progression­free survival was 3.7 months 
(95% CI, 3.0 to 5.3), and the median overall 
survival was 8.6 months (95% CI, 6.2 to 11.3) 
(Fig. 2A and 2B). In patients who had a partial 
response or better or a minimal response or bet­
ter, the median overall survival was 15.6 months 
(Fig. 2C).
Safety Profile
The most common adverse events that emerged 
during treatment were thrombocytopenia (in 73% 
of the patients), fatigue (in 73%), nausea (in 
72%), and anemia (in 67%) (Table 3). The most 
common grade 3 or 4 adverse events were 
thrombocytopenia (in 59% of the patients), ane­
mia (in 44%), hyponatremia (in 22%), and neu­
tropenia (in 21%). Thrombocytopenia occurred 
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more frequently in patients who had thrombocy­
topenia at baseline than in those who did not 
(Fig. S2 in the Supplementary Appendix), and six 
patients with thrombocytopenia of grade 3 or 
higher had a concurrent bleeding event of grade 3 
or higher. Most nonhematologic adverse events 
were limited in severity to grades 1 or 2, with 
only 10% of patients having grade 3 nausea and 
3% having grade 3 vomiting.
In all, 18% of the patients discontinued study 
treatment because of an adverse event considered 





Median (range) — yr 65.2 (40–86)
Distribution — no. (%)
18–50 yr 8 (7)
51–64 yr 52 (43)
65–75 yr 44 (36)
>75 yr 18 (15)
Male sex — no. (%) 71 (58)




Missing data 4 (3)
Chromosomal abnormality — no. (%)





Median time since initial diagnosis (range) — yr 6.6 (1.1–23.4)
Median no. of previous treatment regimens (range) 7 (3–18)
Previous therapies to which the disease was refractory — no. (%)§
≥1 Immunomodulatory drug, ≥1 proteasome inhibitor, and daratumumab 122 (100)
Carfilzomib, pomalidomide, and daratumumab 117 (96)
Carfilzomib, lenalidomide, pomalidomide, and daratumumab 101 (83)
Bortezomib, carfilzomib, pomalidomide, and daratumumab 94 (77)
Bortezomib, carfilzomib, lenalidomide, pomalidomide, and daratumumab¶ 83 (68)
*  A total of 123 patients were enrolled; 1 patient did not meet eligibility criteria, so 122 patients were included in the 
modified intention-to-treat population. Percentages may not total 100 because of rounding.
†  Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with higher scores reflect-
ing greater disability.
‡  This category includes any of del(17p)/p53, t(14;16), t(4;14), or 1q21 (1q gain >2).
§  The disease was defined as refractory to an antimyeloma therapy if the best response to the therapy was stable disease 
or worse or if the patient had progression or a relapse either during treatment or within 60 days after discontinuing the 
therapy.
¶  Myeloma that was refractory to these five agents was considered to be penta-refractory.
Table 1. Baseline Demographic and Clinical Characteristics in the Modified Intention-to-Treat Population.*
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dexamethasone, although such determinations 
for a new agent are imprecise (Table S5 in the 
Supplementary Appendix). Adverse events lead­
ing to dose modification or interruption oc­
curred in 80% of the patients, with the majority 
of events occurring in the first two cycles. The 
most common adverse events leading to dose 
reduction or interruption were thrombocytope­
nia (in 43% of the patients), fatigue (in 16%), 
and neutropenia (in 11%). Supportive care — in­
cluding granulocyte colony­stimulating factors, 
thrombopoietin­receptor agonists, appropriate 
f luid and caloric intake, appetite stimulants, 
psychostimulants, and additional antinausea 
agents — usually reduced the intensity or dura­
tion of adverse events. Side effects were revers­
ible without evidence of toxic effects in major 
organs (treatment­related cardiac, pulmonary, 
hepatic, or renal dysfunction of grade 3 or 
higher) or cumulative toxic effects, with irreversible 
acute kidney injury reported in one patient (1%).
Serious adverse events occurred in 63% of the 
patients, with pneumonia (in 11%) and sepsis 
(in 9%) being the most common (Table S6 in the 
Supplementary Appendix). A total of 28 patients 
died during the study — 16 from disease pro­
gression and 12 from an adverse event. In the 12 
patients with these adverse events, 2 events were 
assessed by the investigator as being related to 
treatment (pneumonia with concurrent disease 
progression [in 1 patient] and sepsis [in 1]).
Biomarkers of Selinexor Response in Multiple 
Myeloma
The binding of selinexor to XPO1 leads to rapid 
inactivation of nuclear export, XPO1 protein deg­
radation, and induction of XPO1 mRNA tran­
scription (without new protein production).9 XPO1 
mRNA induction is one pharmacodynamic mark­
er in selinexor­treated patients, as observed from 
blood samples obtained before and after selinexor 












Total 122 32 (26) 48 (39)
Previous therapies to which the disease was refractory
Bortezomib, carfilzomib, lenalidomide, pomalidomide,  
and daratumumab
83 21 (25) 31 (37)
Carfilzomib, lenalidomide, pomalidomide, and daratumumab 101 26 (26) 37 (37)
Bortezomib, carfilzomib, pomalidomide, and daratumumab 94 25 (27) 36 (38)
Carfilzomib, pomalidomide, and daratumumab 117 31 (26) 45 (38)
R-ISS disease stage
I 20 7 (35) 10 (50)
II 78 21 (27) 32 (41)
III 23 4 (17) 6 (26)
Measurable free light chains
Yes 35 15 (43) 19 (54)
No 87 17 (20) 29 (33)
High-risk cytogenetic abnormality† 65 12 (18) 24 (37)
*  Overall response was defined as a partial response (≥50% reduction in the serum level of myeloma protein) or better, 
and clinical benefit was defined as a minimal response (≥25% to <50% reduction in the serum level of myeloma protein) 
or better. Among the 122 patients, the best response to therapy was a stringent complete response in 2 (2%), a very 
good partial response in 6 (5%), a partial response in 24 (20%), a minimal response in 16 (13%), stable disease in 48 
(39%), and progressive disease or disease that could not be evaluated for response in 32 (26%). R-ISS denotes Revised 
International Staging System.
†  This category included any of del(17p)/p53, t(14;16), t(4;14), or 1q21 (1q gain >2).
Table 2. Overall Response and Clinical Benefit.*
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coid receptor nuclear localization (Fig. S5 in the 
Supplementary Appendix).25,26 A model based on 
a linear discriminant analysis classifier that was 
trained on 35 pretreatment patient samples, includ­
ing 16 obtained from patients who had a response 
and 19 from patients who did not have a re­
sponse, identified four master regulators: IRF3, 
ARL2BP, ZBTB17, and ATRX (Fig. S7 in the Sup­
plementary Appendix). The four­protein classifier 
had a high predictive performance according to 
leave­one­out cross­validation (area under the 
receiver­operating­characteristic curve [AUC], 0.862; 
95% CI, 0.741 to 0.982). The four­protein classifier 
was then validated in an independent, blinded 
analysis of 12 samples obtained from patients 
with myeloma who were enrolled in Parts 1 and 2 
of the STORM study (AUC, 0.770; 95% CI, 0.456 
to 1.000). Specifically, four of five patients who 
had a response and six of seven who did not have 
a response to selinexor were correctly identified 
by the marker, yielding a prediction accuracy of 
83% (95% CI, 55 to 95). Training the classifier 
with the use of differential gene­expression data 
alone produced no effective classification.
Discussion
In this trial, 26% of the patients with penta­
exposed, triple­class refractory myeloma who 
received oral selinexor, a first­in­class XPO1 
inhibitor, with dexamethasone twice weekly had 
a partial response or better. Two patients had 
stringent complete responses, and 6 had very 
good partial responses. Although all patients 
entered the study with progressive disease, 26 
(21%) had persistent disease progression or their 
disease could not be evaluated for response. 
Among the patients who had a response, efficacy 
was consistent across subgroups, including pa­
tients with high­risk cytogenetic abnormalities 
(53% of the patients).
The results of this study are notable for sev­
eral reasons. The trial was permissive, allowing 
patients with reduced renal function, thrombo­
cytopenia, and neutropenia to enroll. These pa­
tients were heavily pretreated, with a median of 
7 previous therapeutic regimens, including a me­
dian of 10 unique antimyeloma agents. Patients 
had rapidly progressing myeloma, with a 22% 
Figure 1. Duration of Response to Treatment.
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≥1 Adverse event 123 (100)
Hematologic adverse events
Thrombocytopenia 12 (10) 6 (5) 31 (25) 41 (33) 90 (73)
Anemia 7 (6) 22 (18) 53 (43) 1 (1) 83 (67)
Neutropenia 7 (6) 16 (13) 22 (18) 4 (3) 49 (40)
Leukopenia 8 (7) 16 (13) 17 (14) 0 41 (33)
Lymphopenia 2 (2) 4 (3) 10 (8) 4 (3) 20 (16)
Nonhematologic adverse events
Fatigue 16 (13) 43 (35) 31 (25) 0 90 (73)
Nausea 34 (28) 42 (34) 12 (10) 0 88 (72)
Decreased appetite 22 (18) 41 (33) 6 (5) 0 69 (56)
Decreased weight 34 (28) 27 (22) 1 (1) 0 62 (50)
Diarrhea 32 (26) 15 (12) 9 (7) 0 56 (46)
Vomiting 22 (18) 21 (17) 4 (3) 0 47 (38)
Hyponatremia 18 (15) 0 26 (21) 1 (1) 45 (37)
Upper respiratory tract infection 3 (2) 23 (19) 2 (2) 0 28 (23)
Constipation 16 (13) 9 (7) 2 (2) 0 27 (22)
Dyspnea 11 (9) 11 (9) 5 (4) 0 27 (22)
Cough 14 (11) 7 (6) 0 0 21 (17)
Hypokalemia 10 (8) 3 (2) 8 (7) 0 21 (17)
Insomnia 13 (11) 6 (5) 2 (2) 0 21 (17)
Mental status changes 7 (6) 7 (6) 7 (6) 0 21 (17)
Pneumonia 0 8 (7) 10 (8) 1 (1) 21 (17)†
Dizziness 14 (11) 5 (4) 0 0 19 (15)
Pyrexia 11 (9) 8 (7) 0 0 19 (15)
Epistaxis 11 (9) 3 (2) 1 (1) 0 15 (12)
Fall 9 (7) 4 (3) 2 (2) 0 15 (12)
Hyperglycemia 2 (2) 3 (2) 8 (7) 0 13 (11)
Peripheral edema 8 (7) 3 (2) 2 (2) 0 13 (11)
Blurred vision 8 (7) 3 (2) 2 (2) 0 13 (11)
*  Shown are events that occurred in at least 10% of the patients. Adverse events were graded according to the National 
Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.23
†  The total includes two events of grade 5.
Table 3. Adverse Events That Emerged during Treatment.*
Figure 2 (facing page). Kaplan–Meier Analysis of Progression-free Survival, Overall Survival, and Overall Survival According to Response.
CI denotes confidence interval, MR minimal response, NE not able to be evaluated, PD progressive disease, PR partial response, and SD 
stable disease. Tick marks indicate censored data.
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increase in disease burden in the 12 days from 
screening to initial therapy. These characteris­
tics are consistent with the growing population 
of patients who have exhausted available thera­
pies but still desire to continue therapy.
Given the rapid progression of penta­exposed, 
triple­class refractory myeloma, the window of 
opportunity to prevent further illness and death 
is small. Therefore, the regimen that was used 
in the STORM study began with a high dose of 
selinexor to achieve rapid disease control. Because 
most patients involved in the study were older 
and frail, with limited end­organ reserve and at 
increased risk for adverse events, dose modifica­
tions were anticipated and were specified along 
with supportive care in the protocol. The adverse 
events that were observed in the study were a func­
tion of dose, schedule, and baseline clinical char­
acteristics (e.g., cytopenias). Thrombocytopenia, 
which is due in part to inhibition by selinexor of 
thrombopoietin signaling in early megakaryo­
poiesis, was reversible and was managed with 
dose interruptions and thrombopoietin­receptor 
agonists.27 Although this study establishes the 
activity of selinexor with dexamethasone, com­
bination regimens are typically used in patients 
with myeloma. Preclinical studies of selinexor 
show enhancement of IκB, which supports its 
synergy in combination with proteasome inhibi­
tors, additivity with immunomodulatory drugs, 
and sensitization of myeloma cells to anti­CD38 
monoclonal antibodies.28­30
In conclusion, the results of the STORM Part 2 
study showed that oral selinexor with low­dose 
dexamethasone induced responses in 26% of pa­
tients with refractory myeloma. The most com­
mon toxic effects of grade 3 or higher included 
thrombocytopenia without bleeding, anemia, neu­
tropenia without fever, and hyponatremia.
A data sharing statement provided by the authors is available 
with the full text of this article at NEJM.org.
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